C43 - Cosmo Pharmaceuticals NV
Executive Summary
Cosmo Pharmaceuticals NV (C43) is a Dublin-headquartered specialty pharmaceutical company that develops and commercialises treatments in gastrointestinal, dermatology and related niche therapy areas, and also operates a contract development and manufacturing (CDMO) business. The group holds a recognised position in its specialist fields through a portfolio of approved products, notably its gastroenterology franchise, alongside emerging dermatology assets and a proprietary endoscopy platform. The company is publicly listed and reports in euros, with primary trading on the SIX Swiss Exchange under the ticker COPN and additional trading on the Xetra venue under C43.
The investment case rests on continued execution against 2026 guidance, specifically recurring revenues guided to EUR 98 - 102 million and total revenues of EUR 105 - 110 million with EBITDA of EUR 10.5 - 13.5 million, which represents the principal near-term catalyst as H1 2026 results land. For the thesis to play out, partner-led commercialisation of Clascoterone must advance without setback, recurring CDMO and product revenue must continue compounding at the mid-teens pace reported in 2025, and the year-end cash position needs to remain close to the targeted ~EUR 200 million to sustain the EUR 2.10 dividend. The primary risk is portfolio and partner concentration disclosed in regulatory filings, where any single regulatory delay or commercial disappointment can disproportionately affect a still-modest revenue base.
OPPORTUNISTIC BUY. Conviction Score: 59/100. The view would upgrade on a clean H1 2026 print consistent with guidance accompanied by demonstrable Clascoterone commercialisation progress, and would downgrade if recurring revenue growth decelerates materially or any disclosed concentration risk crystallises into a specific missed milestone.
Thesis break: A confirmed failure of Clascoterone to progress against its next regulatory milestone, recurring revenue growth decelerating below 5% year-on-year, or any disclosure of a material partner or CDMO client loss that materially impairs the 2026 guidance range.
Business Model
Cosmo generates revenue through three broad streams: licensed specialty pharmaceutical products (principally in gastroenterology, where the group has a long-established commercial footprint), a contract development and manufacturing organisation (CDMO) operation that serves external clients, and a newer dermatology franchise built around Clascoterone. Customer concentration is meaningful: revenues depend on a relatively small number of products and on partner relationships for commercialisation in major geographies, which is why recurring revenue growth rather than headline topline is the metric management emphasises. The 2025 print of EUR 104.2 million total revenue, with recurring revenue up 15% year-on-year and EBITDA of EUR 9.5 million, reflects a business model pivoting from episodic milestone dependency towards a steadier, product-led recurring base.
Margins remain under development as the dermatology and CDMO businesses scale. EBITDA in 2025 exceeded initial guidance, suggesting operating leverage is starting to emerge, but the group still reported a negative earnings per share figure for the year, which means profitability is uneven between segments and dependent on the cadence of milestone receipts. The EUR 2.10 dividend per share, approved at the 2026 Annual General Meeting, is supported by a strong net-cash position rather than by current earnings, and is therefore a capital-allocation signal rather than a coverage signal.
The competitive moat, to the extent one exists, is rooted in specialist domain expertise (GI in particular), proprietary manufacturing capability that supports the CDMO franchise, and a portfolio of regulatory approvals that create switching costs for prescribers. The model is capital-efficient in design because it leans on licensing and distribution partners rather than building a large direct salesforce, but this very design also explains the concentration risk flagged in the thesis: outcomes hinge on a small number of partnerships and approvals.
Financial Snapshot
Recent Catalysts
[12 January 2026] - Cosmo reported strong preliminary unaudited 2025 results, confirming full-year revenue of EUR 104.2 million, recurring revenue growth of 15% year-on-year, EBITDA of EUR 9.5 million above prior guidance, and a year-end cash position that underpins capital return. Source: Cosmo Pharmaceuticals press release via cosmohealthconfidence.com.
[12 January 2026] - The company issued formal 2026 guidance, targeting recurring revenues of EUR 98 - 102 million, total revenues of EUR 105 - 110 million, EBITDA of EUR 10.5 - 13.5 million and year-end cash of approximately EUR 200 million, alongside a proposed EUR 2.10 dividend. Source: Newsfile Corp company announcement.
[April 2026] - Cosmo held its 2026 Annual General Meeting, at which shareholders backed all resolutions on the agenda, including the EUR 2.10 per share dividend, with the ex-dividend date set for 24 April 2026. Source: Stock Titan regulatory news summary.
[March - May 2026] - Management attended three investor conferences with scheduled one-on-one meetings, providing incremental visibility to the institutional buy-side on the 2026 framework. Source: Stock Titan corporate calendar summary.
[H2 2025] - The H2 FY2025 earnings call discussion confirmed the EBITDA beat versus guidance and reaffirmed the recurring revenue acceleration narrative underpinning the scale-up phase. Source: Yahoo Finance earnings call transcript archive.
[April 2026] - The group completed its corporate renaming to Cosmo N.V., reflecting the broadening of its identity beyond pharmaceuticals, though its listing tickers and operational footprint remained unchanged. Source: Yahoo Finance corporate profile update.
Thesis Evaluation
Bull Case (26% weight)
Recurring revenue compounds at the mid-teens pace reported in 2025, Clascoterone progresses cleanly through its next regulatory and commercial milestones, and CDMO wins contribute incremental high-margin backlog. EBITDA lands in the upper half of 2026 guidance at EUR 13.5 million, cash approaches the EUR 200 million target, and the market re-rates the shares as a credible specialty dermatology and CDMO platform rather than a one-product story. EUR90 over a 12-month horizon.
Base Case (49% weight)
Recurring revenue growth tracks management's EUR 98 - 102 million guidance, EBITDA prints within the EUR 10.5 - 13.5 million range, and the dividend is maintained from cash without requiring earnings cover. Clascoterone progress is incremental rather than transformational, and the shares re-rate modestly as visibility on the dermatology and CDMO franchises improves. EUR75 over a 12-month horizon.
Bear Case (25% weight)
A regulatory or partner-related setback on Clascoterone, or a slowdown in recurring revenue growth as the CDMO cycle softens, undermines the scale-up narrative and the shares revert towards the lower end of the 52-week range. EBITDA misses guidance, the dividend becomes harder to defend from cash alone, and the market applies a concentration-risk discount to the dermatology and CDMO optionality. EUR55 over a 12-month horizon.
Key Risks
- Portfolio and partner concentration: Cosmo's revenue base remains dependent on a small number of products and commercialisation partners, so a single regulatory delay or partner disappointment can disproportionately affect the topline. Estimated probability: 35%. Impact: severe.
- Clascoterone regulatory and commercial execution: Progress of the dermatology franchise is a key plank of the recurring revenue acceleration thesis, and any setback to the next regulatory milestone or partner-led launch would directly impair the bull case. Estimated probability: 30%. Impact: severe.
- Negative reported earnings despite EBITDA improvement: The 2025 print shows ongoing bottom-line losses, which means the EUR 2.10 dividend is funded from cash rather than earnings and is therefore sensitive to any deterioration in the net-cash position. Estimated probability: 40%. Impact: moderate.
- CDMO cycle and customer concentration: The CDMO segment is exposed to biotech funding cycles and to a limited number of large clients, both of which can drive lumpiness in recurring revenue growth. Estimated probability: 35%. Impact: moderate.
- Currency and European listing liquidity: Cosmo reports in euros with a Swiss primary listing, so sterling-based investors are exposed to EUR/CHF moves and to the comparatively thin liquidity of mid-cap Swiss pharma names. Estimated probability: 50%. Impact: low.
- Re-rating risk from guidance disappointment: The shares have begun to embed 2026 guidance, so even a modest miss on recurring revenue or EBITDA versus the EUR 98 - 102 million and EUR 10.5 - 13.5 million ranges could trigger a sharp de-rating. Estimated probability: 30%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: A long-only, small- and mid-cap specialist investor with a minimum holding period of 12 - 18 months who is comfortable with a still-loss-making but EBITDA-positive specialty pharma story, can tolerate concentration risk in exchange for capital-efficient optionality, and is comfortable holding a Swiss-listed euro-denominated name. The investor should be comfortable with a mid-teens recurring-revenue-growth profile and with a dividend that is cash-funded rather than earnings-covered at this stage.
Avoid if: You require current earnings cover for the dividend, prefer to avoid single-product or single-partner concentration in healthcare, cannot tolerate interim drawdowns of 25 - 40% as demonstrated by the existing 52-week range, or need deep daily liquidity typical of large-cap pharma. Short-term momentum traders and investors without patience for the lumpy, milestone-driven cadence of a specialist European pharma name should also look elsewhere.
Recommendation
BLOCKED - methodology gate failed (frameworkRuleCheck). The model score is 59/100 (OPPORTUNISTIC BUY), but this is not an actionable recommendation until the gate is verified.
Entry levels under review.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Flat.
| Report date | Conviction |
|---|---|
| 2026-08-08 | 59 |
| 2026-07-25 | 59 |
| 2026-06-28 | 59 |
| 2026-05-30 | 73 |
| 2026-04-27 | 81 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow was reviewed, including company press releases, regulatory filings summaries, earnings call transcripts, investor conference announcements, and financial news wire coverage of the 2025 preliminary results, 2026 guidance, the AGM voting outcome and the corporate renaming to Cosmo N.V.
Primary source types: Company press releases, earnings call transcripts, investor relations materials, regulatory and corporate-action announcements (including AGM voting results and ex-dividend dates), and third-party financial news wires covering the H2 2025 results and 2026 guidance framework.
Key sources
- Cosmo Pharmaceuticals N.V. (C43.F) Stock Price, News, Quote & History - Yahoo Finance
- Cosmo Pharmaceuticals NV (C43.MU) Stock Price, News, Quote & History - Yahoo Finance
- C43-DE: Cosmo Pharmaceuticals NV - Stock Price, Quote and News - CNBC
- C43-FF: Cosmo Pharmaceuticals NV - Stock Price, Quote and News - CNBC
- C43: COSMO Pharmaceuticals NV Stock Price Quote - Frankfurt - Bloomberg
- Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
- Cosmo | Cosmo Enters Scale Up Phase with
- Cosmos Health signs five-year manufacturing deal with Pharmex By Investing.com
- Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and
- Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework | Nasdaq
Data correct as of 2026-08-08